Introduction:
Sabizabulin is a first-in-class, oral agent that inhibits microtubule polymerization disrupting the cytoskeleton and arresting cellular proliferation. In prostate cancer, targeted inhibition of microtubule polymerization further blocks the transport of the androgen receptor into the nucleus. A Phase 1b/2 clinical study was conducted to establish the MTD and evaluate the preliminary efficacy in men with metastatic castrate resistant prostate cancer (mCRPC) who progressed on at least one androgen receptor targeting agent (ARTA). The most common AEs reported were mild to moderate diarrhea, fatigue, nausea, and vomiting with no clinically relevant neurotoxicity or neutropenia. In the Phase 1b/2, in all evaluable patients that would qualify for the VERACITY study (n=26), the ORR was 23.1%. Median radiographic progression free survival was >12 months (range 6-28+ months) in the Phase 1b portion including responses >two years. The revised formulation for use in the Phase 3 study, with improved bioavailability, is 32mg PO qd.
Methods:
VERACITY is an ongoing Phase 3 multicenter, randomized, active-control study designed to evaluate sabizabulin in the treatment of mCRPC who have progressed on at least one ARTA. Patients on the study will be chemotherapy naive. Subjects (n=245) are being randomized in a 2:1 ratio to receive sabizabulin (32 mg/d oral) or active control (alternative ARTA) and will remain on study until radiographic progression-free survival (rPFS). Randomization will be stratified by: measurable disease vs bone-only disease and by prior exposure to ARTA (progressed on one vs more than one prior ARTA). The primary efficacy endpoint of the study is median rPFS. Secondary endpoints include: objective response rate (ORR), duration of objective response, overall survival and time to intravenous (IV) chemotherapy. The Phase 3, VERACITY registration clinical trial is current ongoing in approximately 45 clinical sites with enrollment anticipated to be completed in 2022 and with unblinded results presented in 2023.
Results:
Conclusion:
Funding: Veru Inc
Image(s) (click to enlarge):
PHASE 3 VERACITY CLINICAL STUDY OF SABIZABULIN IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED ON AN ANDROGEN RECEPTOR TARGETING AGENT
Category
Prostate Cancer > Metastatic
Description
Poster #222
Friday, Dec 3
3:00 p.m. - 4:00 p.m.
Prostate 4
Presented By: Robert Dreicer
Authors:
Robert Dreicer
Franklin Chu
David Cahn
Robert H. Getzenberg
Domingo Rodriguez
K. Gary Barnette
Mitchell S. Steiner
Daniel R. Saltzstein
Ronald Tutrone
Neal Shore